# Tasonermin

Tasonermin (Beromun, Belpharma s.a.) has 1 EU-approved indication in 1 tumour type.

## Approved indications

### Soft tissue sarcoma

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| None | + melphalan via mild hyperthermic isolated limb perfusion (ILP) | Advanced | As an adjunct to surgery for subsequent removal of the tumour to prevent or delay amputation, or in the palliative situation |

## Products

### Beromun

- Company: Belpharma s.a.
- Target: Recombinant tumor necrosis factor alfa
- ATC: L03AX11
- EU approval: 12 Apr 1999
- Label revised: 28 May 2026
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/beromun-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/beromun-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/beromun

Mechanism (SmPC section 5.1): Tasonermin directly inhibits tumour cell proliferation, disrupts tumour vasculature leading to microvascular thrombosis, and activates immune cells to promote antitumour activity.

## Label wording

- **Tasonermin** (Beromun), Soft tissue sarcoma, advanced: “Beromun is indicated in adults. as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated limb perfusion (ILP).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/beromun-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/tasonermin